Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

Rhea-AI Summary

Integra LifeSciences (Nasdaq:IART) has appointed Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings over 20 years of surgical and leadership experience from major MedTech companies, including Siemens Healthineers and Johnson & Johnson.

In his new role, Dr. Turner will lead worldwide medical affairs and clinical development activities, while maintaining his clinical practice. His extensive background includes serving as chief medical officer at Siemens Endovascular Robotics and program director at the Medical University of South Carolina. Dr. Turner has authored over 150 peer-reviewed publications and participated in more than 70 research studies.

Positive

• Appointment of highly qualified CMO with over 20 years of surgical and leadership experience
• New CMO brings extensive research background with 150+ publications and 70+ research studies
• Dual role maintaining clinical practice while serving as CMO provides ongoing practical insights
• Strong industry experience from leadership roles at Siemens Healthineers and Johnson & Johnson

Negative

• None.

News Market Reaction

+1.98%

1 alert

+1.98% News Effect

On the day this news was published, IART gained 1.98%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice

PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer.

Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world’s largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providing patients with neurosurgical care.

“Dr. Turner’s extensive medical and clinical experience and expertise will be significant assets to Integra as we strengthen our focus on building robust clinical evidence,” said Mojdeh Poul, president and chief executive officer, Integra LifeSciences. “His proven leadership and passion for advancing safety and quality will help us continue to deliver innovative solutions and transform patient care for the millions around the world.”

Prior to joining Integra, Dr. Turner held various leadership roles at Siemens Healthineers, including his most recent position as the chief medical officer for Siemens Endovascular Robotics. Prior to this, he was a medical director for Cerenovus, a Johnson & Johnson MedTech company. Additionally, Dr. Turner served as the program director of the neurosurgery residency program and was the chief of neuroscience (neurological surgery, neurology, and ENT) at the Medical University of South Carolina.

“I am excited to be joining Integra, an organization deeply committed to providing best-in-class, evidence-based products that help restore patient lives,” said Dr. Raymond Turner. “I look forward to working closely with both the Integra team and our healthcare partners to improve patient outcomes and uphold the highest standards of care.”

Dr. Turner served as a practicing surgeon at PRISMA Health and most recently, at Intermountain Health in Billings, Montana. He currently serves as an examiner for the American Board of Neurological Surgery.

Dr. Turner completed his undergraduate degree in biology at Sacred Heart University in Connecticut. He obtained his medical degree at Karol Marcinkowski University of Medical Sciences in Poznan, Poland. Dr. Turner completed his residency in neurological surgery and his fellowship in endovascular neurosurgery at the Cleveland Clinic. He has authored more than 150 peer-reviewed publications and has been involved in more than 70 pre-clinical and clinical research studies.

About Integra LifeSciences

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1bd1b51-a9bb-4545-b463-a79108abf93f

FAQ

Who is the new Chief Medical Officer of Integra LifeSciences (IART)?

Dr. Raymond Turner has been appointed as the new corporate vice president and chief medical officer of Integra LifeSciences. He brings over 20 years of surgical and leadership experience from major MedTech companies.

What will be Dr. Turner's responsibilities at Integra LifeSciences (IART)?

Dr. Turner will lead worldwide medical affairs and clinical development activities, including clinical research, trial operations, evidence generation, medical safety and communications, while maintaining his clinical practice.

What is Dr. Raymond Turner's background before joining Integra (IART)?

Dr. Turner previously served as CMO at Siemens Endovascular Robotics, medical director at Cerenovus (Johnson & Johnson), and program director at the Medical University of South Carolina. He has authored 150+ peer-reviewed publications and participated in 70+ research studies.

Where did Dr. Turner complete his medical education and training?

Dr. Turner completed his medical degree at Karol Marcinkowski University in Poland, followed by his residency in neurological surgery and fellowship in endovascular neurosurgery at the Cleveland Clinic.

How will Dr. Turner's appointment impact Integra LifeSciences (IART)?

Dr. Turner's appointment is expected to strengthen Integra's focus on building robust clinical evidence and advancing safety and quality in their innovative healthcare solutions.